– Dr. Stanislav Glezer to join as Executive Vice President and Chief Medical Officer Effective June 21, 2021 –
GOLETA, Calif. – Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that its Board of Directors has appointed Dr. Stanislav Glezer as Inogen’s Executive Vice President and Chief Medical Officer, effective June 21, 2021.
Nabil Shabshab, Inogen’s Chief Executive Officer, said, “On behalf of the Board of Directors, I would like to congratulate Stan on this appointment as I am confident that he will be a tremendous asset to Inogen and a great addition to our executive team. I believe that expanding our clinical expertise and evidence dossier in respiratory therapy will serve us well in our endeavors to drive our market development efforts to eventually increase the penetration of portable oxygen concentrators (POCs) in support of our growth strategy as well as help guide our innovation agenda. I believe Stan’s over 25 years of experience in clinical research and medical affair roles with strong experience in commercial, market access and other areas across a variety of medical technology and biotechnology firms will be a great enabler in building a stronger Inogen and elevating our clinical capabilities overall.”
“I am honored by the opportunity to lead the Medical Affairs, Clinical Research, [and Regulatory] organizations of Inogen in our mission to increase the freedom and independence for respiratory patients and to meaningfully improve clinical outcomes, as demonstrated by clinical evidence, generated in collaboration with health care practitioners and key opinion leaders in our effort to make our technologies the standard of care,” said Dr. Glezer. “I look forward to contributing to the next phase of Inogen’s planned growth as we continue to seek ways to design patient centric outcomes studies to improve access to our best-in-class product offerings, enable prescribers to better serve their patients and enhance our market position and value for our stockholders.”
Most recently, Dr. Glezer, 49, was with Becton, Dickinson and Company, a global medical technology company where he served as the Worldwide Vice President of Medical Affairs for Diabetes Care since September 2018 with Business Development responsibilities added under him since January 2021. Prior to joining Becton Dickinson, Dr. Glezer served as the Chief Medical Officer at Adocia S.A. a biotechnology company, from 2017 to 2018. From 2016 to 2017, Dr. Glezer served as Vice President of Global Medical Affairs at Novo Nordisk, Inc., a healthcare company. Earlier, Dr. Glezer served in a number of roles of progressively increasing seniority, including, Global Project Head for the largest late-stage pipeline asset, Vice President of Evidence and Value & Access, Vice President of Medical Affairs, and Senior Director of Medical Strategy & Operations, for Sanofi S.A., a multinational pharmaceutical company, from 2001 to 2015. Dr. Glezer holds a doctor of medicine from Moscow State University of Medicine and Dentistry and a MBA from California Coast University.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
About Inogen
We are a medical technology company offering innovative respiratory products for use in the homecare setting. We primarily develop, manufacture and market innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Cautionary Note About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements with respect to the announced management and organizational changes, statements concerning or implying Inogen’s future financial performance, trends and opportunities affecting Inogen, and the ability of management personnel to contribute to the development of and increasing patient access to Inogen’s products and technologies, expanding and growing its business, and increasing value for its stockholders. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks related to its announced management and organizational changes, risks arising from the possibility that Inogen will not realize anticipated revenue; the risks related to the COVID-19 public health emergency; the impact of changes in reimbursement rates and reimbursement and regulatory policies; the possible loss of key employees, customers, or suppliers; risks relating to Inogen’s acquisition of New Aera and the integration of New Aera’s business and operations within those of Inogen; risks relating to reimbursement coding of the Tidal Assist© Ventilator (TAV); the possibility that Inogen will not realize anticipated revenue from the technology acquired from New Aera or that expenses and costs will exceed Inogen’s expectations; intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products; and intellectual property risks relating to the acquisition of New Aera, including the risk of intellectual property litigation. In addition, Inogen’s business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business and operating results are contained in Inogen’s Quarterly Report on Form 10-Q for the period ended March 31, 2021 and its subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.